# Bioprocess Containers Market

> Bioprocess Containers Market Report by Type (2D Container, 3D Container, Accessories), Application (Production Process, Upstream Process, Downstream Process), End User (Pharmaceutical Companies, Biotechnology Companies), and Region- Forecast till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 14.0%
- **2025:** USD 3.97 Billion
- **2035:** USD 14.70 Billion
- **Key Players:** Thermo Fisher Scientific Inc., Sartorius AG, Danaher Corporation (Cytiva), Merck KGaA, Corning Incorporated, Avantor Inc., Saint-Gobain Life Sciences, Repligen Corporation

**Report ID:** MRFR/MED/5169-HCR · **Pages:** 100 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** October 26, 2026

**URL:** https://www.marketresearchfuture.com/reports/bioprocess-containers-market-6632

---

## Market Summary

## Bioprocess Containers Market Summary

The Bioprocess Containers Market was valued at USD 3.97 Billion in 2025 and is projected to reach USD 4.52 Billion in 2026, then expand at a CAGR of 14.0% to USD 14.70 Billion by 2035. Two catalysts anchor this outlook. The revised EU GMP Annex 1, operative since August 2023, raised contamination-control expectations for every sterile manufacturing step [2]. Capital is also flowing into outsourced capacity, led by Novo Holdings' USD 16.5 billion acquisition of Catalent, completed in December 2024 [3].

Underneath these figures, manufacturing architecture is evolving. Multilayer polymer bags, tube sets, and aseptic connectors that are pre-sterilized and ready for installation are replacing fixed stainless-steel tanks, clean-in-place skids, and steam-in-place piping. Suppliers are consolidating in response to this change. In February 2025, Thermo Fisher Scientific acquired Solventum's purification and filtration business for approximately USD 4.1 billion, thereby expanding its single-use fluid-handling portfolio [4].

North America's 39.5% share of 2025 revenue is the highest in the world, and it is bolstered by the world's most extensive [biologics](https://www.marketresearchfuture.com/reports/biologics-market-1339) pipeline. The Asia-Pacific region is experiencing the most rapid growth, with a compound annual growth rate (CAGR) of 16.2%. This is due to the development of domestic biomanufacturing capacity in China, India, and South Korea. Europe is the second-ranked region, with Annex 1 compliance enhancements driving container replacement across legacy fill-finish and upstream suites. The Bioprocess Containers Market will be significantly influenced by supply resilience and sustainability over the next decade, in addition to the volume of raw biologics.

## Key Report Takeaways

### • By Type of Container

- 3-D Bioprocess Containers accounted for 43.1% share of the Bioprocess Containers Market in 2025, reflecting their role in large-volume fed-batch reactors.
- 2-D Bioprocess Containers are forecast to grow at a 14.3% CAGR as perfusion and rocking-platform culture scale up.

### • By Application

- Upstream Processing held 51.2% share in 2025, anchored by disposable [bioreactors](https://www.marketresearchfuture.com/reports/bioreactor-market-43158) for mammalian cell culture.
- Downstream Processing is projected to expand at a 14.6% CAGR as buffer, pooling, and viral-inactivation steps move to bags.

### • By End-User

- Biopharmaceutical & Vaccine Manufacturers captured 58.2% share in 2025 through owner-operated multiproduct facilities.
- Contract Development & Manufacturing Organizations (CDMOs) represent the fastest-growing end-user group in the Bioprocess Containers Market, at a 14.9% CAGR.

### • By Region

- North America led with 39.5% share in 2025.
- Asia-Pacific is forecast to grow at a 16.2% CAGR, the highest of any region.
- Europe generated USD 1.11 Billion in 2025 revenue.

## Market Size and Forecast (2021–2035)

Estimates for the Bioprocess Containers Market combine supplier revenue disclosures, biomanufacturing capacity databases, regulatory approval counts, and primary interviews with procurement leads at biopharmaceutical companies and CDMOs. Historical values were reconciled against segment revenue reported by leading suppliers [15][16][22], while forecasts apply installed single-use capacity, pipeline progression, and regional investment programs.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Expanding biologics and biosimilar pipeline | +2.6% | Global, strongest in North America | Long-term (≥4 yr) | [5] |
| Migration from stainless steel to single-use facilities | +2.2% | Global | Medium-term (2–4 yr) | [6][7] |
| CDMO capacity expansion and outsourcing | +1.8% | North America, Europe, Asia-Pacific | Medium-term (2–4 yr) | [3][8] |
| Cell and gene therapy commercialization | +1.5% | North America, Europe | Long-term (≥4 yr) | [9][20] |
| Stricter contamination-control regulation | +1.2% | Europe, spillover globally | Short-term (≤2 yr) | [2] |
| Pandemic preparedness vaccine capacity | +1.0% | Global | Medium-term (2–4 yr) | [10] |
| Asia-Pacific biomanufacturing policy support | +0.9% | Asia-Pacific | Long-term (≥4 yr) | [11][19] |

### Expanding Biologics and Biosimilar Pipeline

Biologics now make up a large and steady share of new drug approvals, and each approved molecule carries recurring consumable demand across clinical and commercial runs. The FDA's Center for Drug Evaluation and Research approved 50 novel drugs in 2024, with monoclonal antibodies and other biologics well represented [5]. Biosimilar entrants following major antibody patent expiries add further volume. Every batch consumes media bags, harvest containers, and buffer storage, so pipeline growth translates directly into container pull-through.

### Migration From Stainless Steel to Single-Use Facilities

Manufacturers increasingly choose single-use bioreactor bags over fixed tanks because the economics favor flexibility. Industry guidance indicates single-use plants can cut capital costs substantially and shorten construction timelines compared with stainless-steel equivalents, while removing cleaning-validation workloads [6]. Facility design references also describe lower water and steam consumption once clean-in-place systems are eliminated [7]. Multiproduct sites benefit most, since changeovers shrink from days of cleaning to hours of bag replacement.

### CDMO Capacity Expansion and Outsourcing

Outsourcing has become a core risk-mitigation strategy for drug developers, and CDMOs are acquiring and building capacity to meet it. Lonza agreed in March 2024 to acquire Genentech's Vacaville biologics site for USD 1.2 billion [8], while Novo Holdings' USD 16.5 billion Catalent purchase reshaped the fill-finish landscape [3]. CDMOs favor standardized single-use suites that switch between client molecules quickly, making them heavy, repeat buyers of containers and assemblies.

### Cell and Gene Therapy Commercialization

Cell and gene therapies run in small, high-value batches that suit closed, disposable processing. The FDA anticipated approving 10 to 20 cell and gene therapy products per year by 2025, signalling the scale of the pipeline entering commercial production [9]. Industry tracking shows hundreds of active clinical programs in regenerative medicine [20]. Each therapy requires sterile bags for expansion, viral vector production, harvest, and cryogenic storage, raising container use per dose.

### Stricter Contamination-Control Regulation

The revised EU GMP Annex 1, operative from August 2023, requires a documented contamination control strategy and favors closed systems and pre-sterilized components [2]. Many European and export-oriented plants responded by replacing open transfers with welded bag-and-tube assemblies. Because Annex 1 also influences inspections by authorities aligned through the [Pharmaceutical](https://www.marketresearchfuture.com/reports/pharmaceutical-market-67551) Inspection Co-operation Scheme, compliance upgrades extend well beyond the European Union, supporting near-term container demand.

### Pandemic Preparedness Vaccine Capacity

Governments and global health bodies now fund standby vaccine capacity that can scale rapidly. CEPI's strategy for 2022–2026 set a USD 3.5 billion funding target to support its 100 Days Mission, which aims to deliver vaccines within 100 days of a new threat [10]. Rapid-response platforms such as mRNA depend on disposable mixing, storage, and formulation bags, because single-use lines can be qualified and redeployed faster than fixed equipment.

### Asia-Pacific Biomanufacturing Policy Support

National programs across Asia-Pacific are subsidizing domestic biologics production. India's Production Linked Incentive scheme for pharmaceuticals carries an outlay of INR 15,000 crore, supporting complex generics and biopharmaceuticals [11]. India's BioE3 policy, approved in August 2024, adds dedicated biomanufacturing hubs [19]. New greenfield plants in the region are designed around single-use equipment from the outset, creating container demand without legacy stainless-steel replacement cycles.

## Restraints

## Restraints Impact Analysis

The restraint estimates below represent directional drag on the Bioprocess Containers Market forecast CAGR. They overlap with drivers and with each other and should be read as relative magnitudes rather than precise subtractions.

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Extractables, leachables, and validation burden | -1.1% | Global | Medium-term (2–4 yr) | [12][13] |
| Plastic waste and sustainability pressure | -0.8% | Europe, North America | Long-term (≥4 yr) | [14] |
| Supply chain concentration and lead-time risk | -0.7% | Global | Short-term (≤2 yr) | [13] |
| Volume ceiling of single-use reactors | -0.6% | Global | Long-term (≥4 yr) | [7] |
| Post-pandemic inventory cycles | -0.5% | North America, Europe | Short-term (≤2 yr) | [15] |

### Extractables, Leachables, and Validation Burden

Polymer films can release compounds into process fluids, so every new container must be supported by extractables data. USP General Chapter <665> establishes a risk-based framework for characterizing plastic components used in drug manufacturing [12], and standardized testing protocols from industry consortia add further requirements [13]. Smaller developers often lack in-house analytical capacity, which slows supplier qualification and delays switching to new container formats.

### Plastic Waste and Sustainability Pressure

Single-use processing replaces water and energy savings with solid plastic waste, most of it incinerated or landfilled. Industry sustainability roadmaps acknowledge that multilayer films are difficult to recycle because of mixed polymer layers and biological contamination [14]. Corporate net-zero targets and European packaging rules increase scrutiny of disposable formats, and some buyers now weigh end-of-life cost when comparing single-use against stainless-steel options.

### Supply Chain Concentration and Lead-Time Risk

A handful of film producers and assembly sites serve most of the global demand. During 2021, lead times for some single-use assemblies stretched to many months as pandemic orders surged, exposing this concentration [13]. Requalifying an alternative supplier can require extensive comparability testing, so manufacturers often hold large safety stocks or delay new single-use projects when supply visibility weakens.

### Volume Ceiling of Single-Use Reactors

Commercial single-use bioreactors generally top out at around 5,000 to 6,000 liters, while stainless-steel tanks routinely exceed 15,000 liters [7]. Blockbuster antibody programs with very high annual demand still favor large fixed tanks because bag costs scale with every batch. This ceiling limits container penetration in the highest-volume commercial plants, even as intensified processing narrows the gap.

### Post-Pandemic Inventory Cycles

Order patterns proved volatile after COVID-19 emergency procurement ended. Leading bioprocess suppliers reported double-digit revenue declines in 2023 as customers drew down inventories built during 2021 and 2022 [15]. Although demand normalized through 2024, the episode showed that stocking cycles can mask underlying consumption, and buyers remain cautious about committing to long-term volume contracts.

## Opportunities

## Bioprocess Containers Market Opportunities

### Greenfield Biomanufacturing in Emerging Markets

India, the GCC states, and Brazil are funding first-generation biologics plants that face no stainless-steel legacy. India's incentive and BioE3 programs [11][19] and the WHO-backed mRNA technology transfer hub in South Africa [23] point to new sites designed around disposable equipment from day one. Suppliers that pair containers with local assembly, training, and regulatory support can lock in long-term consumable contracts in these regions.

### Supply-as-a-Service and Process Data Monetization

Container vendors are shifting toward subscription-style supply agreements that bundle single-use bags, connectors, and guaranteed inventory buffers. Industry trade tracking notes that single-use processing adoption now accounts for over 50% of new biopharma manufacturing facilities, with over 65% of companies increasing single-use investments to boost agility. Sensor-equipped containers capture real-time parameters like dissolved oxygen and temperature to feed digital twin analytics, allowing vendors to monetize data optimization services and establish recurring platform revenues

.

### Cell and Gene Therapy Fill-Finish and Cryogenic Formats

Low-volume, cryogenic-rated bags and closed transfer sets are an underserved category as cell and gene therapies reach commercial scale [9][20]. Products validated for vapor-phase liquid nitrogen storage and integrity after freeze-thaw command premium pricing. CDMOs specializing in advanced therapies are the primary early adopters of these formats.

### Recyclable and Lower-Carbon Film Technologies

Mono-material films, bio-based polyethylene, and chemical recycling partnerships directly address single-use plastic waste restraints. Industry publications report that adoption of disposable technologies achieves up to a 40% reduction in capital expenditure compared to traditional facilities, though solid waste generation remains a critical concern. Suppliers that successfully validate recyclable film structures with complete extractables data gain strategic advantages in institutional procurement tenders across Europe, where sustainability metrics and environmental scoring increasingly govern vendor selection.

### mRNA and Rapid-Response Vaccine Platforms

Standby vaccine capacity funded under pandemic preparedness programs [10] requires disposable mixing, lipid nanoparticle formulation, and storage bags held in reserve. Pre-qualified container kits that can be deployed quickly across multiple sites present a recurring contract opportunity with governments and vaccine developers.

## Future Outlook

## Bioprocess Containers Market Future Outlook

### Continuous and Intensified Processing

Perfusion upstream and connected downstream trains will become standard for new biologics capacity over the decade. Continuous lines run longer campaigns with smaller reactors, increasing demand for media, harvest, and buffer bags per unit of output. Process intensification guidance from facility engineering bodies [7] supports this move, and the Bioprocess Containers Market will tilt toward flat-panel formats and high-capacity buffer storage as a result.

### Sensor-Integrated and Digitally Connected Containers

Pre-installed single-use sensors for pH, dissolved oxygen, and biomass are moving from premium options to default specifications. Connected containers allow real-time release testing and digital batch records, which regulators increasingly accept within risk-based frameworks [12]. Vendors that standardize data interfaces across bags, connectors, and controllers will capture service revenue beyond the physical product.

### Circularity and Lower-Carbon Materials

Sustainability will shape material choices more than any other factor after 2030. Industry roadmaps target recyclable or recoverable single-use components and lower lifecycle emissions [14]. Expect mono-material films, take-back programs, and chemical recycling partnerships to scale, along with procurement scoring that rewards lower carbon per batch.

### Regionalized and Resilient Supply Networks

Pandemic shortages and geopolitical scrutiny, including the BIOSECURE Act passed by the US House in 2024 [18], are pushing buyers toward dual-sourced, regionally manufactured containers. Leading suppliers are adding assembly sites in Asia-Pacific and North America to reduce lead times. Standardized film specifications developed by industry consortia [13] will make supplier switching faster and less costly.

## Segment Insights

## Bioprocess Containers Market Segmentation

The Bioprocess Containers Market is segmented by type of container, application, and end-user, with each dimension reflecting a different balance between installed-base demand and emerging processing formats.

### By Type of Container

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| 2-D Bioprocess Containers | 14.3% CAGR | Perfusion culture, rocking platforms, media and sample storage |
| 3-D Bioprocess Containers | 43.1% share | Large-volume fed-batch reactors and bulk fluid storage |
| Others | USD 0.51 Billion | Tank liners, transfer bags, and specialty formats |

Within the Bioprocess Containers Market, 3-D Bioprocess Containers lead because large fed-batch antibody runs need structurally supported bags with working volumes up to several thousand liters. 2-D Bioprocess Containers grow fastest as flexible bioprocess bags on rocking platforms improve oxygen transfer for perfusion and seed-train work. Others, including tank liners and transfer bags, serve mixing and fluid movement. Multilayer film and gamma-stable sensor advances are narrowing performance gaps between geometries.

### By Application

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Upstream Processing | 51.2% share | Disposable bioreactors for mammalian cell culture |
| Downstream Processing | 14.6% CAGR | Single-use buffer, pooling, and viral-inactivation steps |
| Process Development / Scale-up | USD 0.38 Billion | Clinical-stage pipelines and tech-transfer runs |
| Fill-Finish Operations | 8.4% share | Closed formulation and cell therapy fill lines |

Upstream Processing remains the largest application in the Bioprocess Containers Market because disposable bioreactors remove cleaning steps and cut batch turnaround. Downstream Processing grows fastest as buffer preparation, pooling, and viral inactivation shift to bags under Annex 1 closed-system expectations [2]. Process Development / Scale-up benefits from busy clinical pipelines and frequent technology transfers. Fill-Finish Operations rely on pre-sterilized liners and manifolds that protect small, high-value batches.

### By End-User

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Biopharmaceutical & Vaccine Manufacturers | 58.2% share | Owner-operated multiproduct facilities and vaccine platforms |
| Contract Development & Manufacturing Organizations (CDMOs) | 14.9% CAGR | Outsourcing growth and standardized single-use suites |
| Others | USD 0.36 Billion | Academic, research institute, and government facilities |

Biopharmaceutical & Vaccine Manufacturers form the core of Bioprocess Containers Market demand, operating multiproduct plants where bags enable rapid molecule changeover across antibodies, fusion proteins, and vaccines. Contract Development & Manufacturing Organizations (CDMOs) grow fastest, supported by acquisitions such as Catalent and Vacaville [3][8] and greenfield sites built without stainless steel. Others, including academic and government facilities, purchase containers for research, pilot production, and pandemic-preparedness reserves.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 39.5% share | Biologics pipeline depth, CDMO acquisitions, cell and gene therapy launches |
| Europe | USD 1.11 Billion | Annex 1 compliance upgrades, biosimilar production, sustainability-led procurement |
| Asia-Pacific | 16.2% CAGR | Greenfield single-use plants, national biomanufacturing incentives, CDMO expansion |
| South America | 5.0% share | Public vaccine production, biosimilar localization |
| Middle East & Africa | USD 0.16 Billion | Vaccine self-sufficiency programs, mRNA technology transfer |
| Total | USD 3.97 Billion | — |

Regional demand in the Bioprocess Containers Market follows the geography of biologics manufacturing capacity: North America and Europe hold the installed base, while Asia-Pacific drives incremental growth through new plant construction.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 84.5% of regional share | Largest biologics pipeline and CDMO base |
| Canada | 13.6% CAGR | Domestic vaccine manufacturing investment |
| Mexico | USD 0.09 Billion | Biosimilar production and nearshoring of assembly |

The United States dominates regional demand through its concentration of biologics developers, contract manufacturers, and advanced therapy companies. CDER's 50 novel drug approvals in 2024 [5] and major capacity deals such as Lonza's Vacaville acquisition [8] keep consumable pull-through high. Canada has invested heavily in domestic vaccine and biologics capacity since the pandemic, while Mexico benefits from biosimilar growth and nearshored single-use assembly operations serving US customers.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | USD 0.30 Billion | Supplier manufacturing base and large biologics plants |
| United Kingdom | 13.4% CAGR | Cell and gene therapy clusters |
| France | 15.0% of regional share | Vaccine production and biomanufacturing incentives |
| Italy | USD 0.11 Billion | Contract fill-finish capacity |
| Spain | 13.1% CAGR | Biosimilar and vaccine manufacturing growth |
| Rest of Europe | 23.0% of regional share | Antibody and CDMO sites in Switzerland, Ireland, and Nordic markets |

Europe's share of the Bioprocess Containers Market rests on regulatory pressure and a dense manufacturing base. Annex 1 [2] has pushed sterile manufacturers to replace open transfers with closed assemblies, a change that touches nearly every legacy site. Germany hosts major supplier production and large biologics plants, while the United Kingdom's advanced therapy clusters support specialized low-volume formats. Sustainability criteria are increasingly written into European tenders [14].

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 38.0% of regional share | Domestic biologics and CDMO scale-up |
| Japan | USD 0.17 Billion | Biosimilar promotion and regenerative medicine framework |
| India | 19.1% CAGR | PLI scheme and BioE3 biomanufacturing hubs |
| Australia | 6.5% of regional share | Onshore mRNA and vaccine capacity |
| South Korea | USD 0.13 Billion | Large-scale CDMO plant construction |
| Rest of Asia-Pacific | 15.4% CAGR | Singapore and Southeast Asian biologics investment |

Asia-Pacific is where the Bioprocess Containers Market adds the most new capacity, because regional plants are built single-use first. China leads volume through domestic antibody developers and CDMOs, although US legislative scrutiny of certain Chinese biotechnology firms is prompting some sponsors to diversify [18]. India is the fastest-growing country, supported by INR 15,000 crore in pharmaceutical incentives [11] and the BioE3 policy [19]. South Korea's large CDMO campuses add substantial consumable demand.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.0% of regional share | Public vaccine institutes and biosimilar partnerships |
| Argentina | 12.8% CAGR | Biotechnology exports and vaccine production |
| Rest of South America | USD 0.04 Billion | Emerging biosimilar manufacturing |

Brazil anchors regional demand through state-linked vaccine producers and technology-transfer partnerships for biologics and biosimilars. Argentina has an established biotechnology sector with export-oriented vaccine and therapeutic protein production. Across the region, currency volatility and import dependence on films and assemblies raise costs, so buyers favor multi-year supply agreements that stabilize pricing and availability.

### Middle East & Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| GCC | 15.8% CAGR | National health-security and pharmaceutical localization programs |
| South Africa | 24.0% of regional share | mRNA technology transfer hub and vaccine manufacturing |
| Rest of Middle East & Africa | USD 0.05 Billion | Regional vaccine self-sufficiency initiatives |

GCC states are funding domestic biologics and vaccine plants as part of economic diversification and health-security strategies, and new facilities are typically specified with disposable equipment. South Africa hosts the WHO-backed mRNA technology transfer programme [23], which trains manufacturers across low- and middle-income countries. Elsewhere in Africa, regional vaccine manufacturing goals are creating early-stage demand for standardized single-use kits.

## Competitive Benchmarking

## Competitive Benchmarking

The Bioprocess Containers Market is moderately concentrated, with an estimated Herfindahl-Hirschman Index of roughly 900 to 1,100. The top five suppliers are estimated to hold about 50–60% of revenue, led by vertically integrated bioprocess companies that own film extrusion, bag assembly, and sterilization. A long tail of specialists competes on custom assemblies, regional service, and advanced therapy formats, keeping the remainder fragmented.

| Company | Est. Revenue Share Range | Key Offerings for Bioprocess Containers Market | Strategic Positioning |
| --- | --- | --- | --- |
| Thermo Fisher Scientific Inc. | ~14–18% | 2-D and 3-D bags, single-use bioreactor systems, fluid transfer assemblies | Broadest portfolio; expanding filtration through acquisition [4] |
| Sartorius AG | ~12–16% | Flexsafe bags, single-use bioreactors, fluid management assemblies | Integrated film-to-system supplier with strong European base |
| Danaher Corporation (Cytiva) | ~11–15% | Fortem film bags, Xcellerex bioreactors, mixing systems | End-to-end bioprocess platform with global service network |
| Merck KGaA | ~9–12% | Mobius single-use bags and assemblies, mixing systems | Process development and viral vector capabilities |
| Corning Incorporated | ~4–6% | Cell culture vessels, HYPERStack, storage bags | Strength in adherent culture and advanced therapies |
| Avantor Inc. | ~3–5% | Custom single-use assemblies, fluid handling components | Custom configuration and distribution reach |
| Saint-Gobain Life Sciences | ~3–5% | Biocontainers, tubing, aseptic connectors | Polymer and tubing expertise |
| Repligen Corporation | ~2–4% | Fluid management assemblies, filtration-integrated systems | Downstream and fluid-path specialist |
| Entegris Inc. | ~2–4% | Single-use bags, cryogenic and freeze-thaw containers | Advanced materials and cold-chain formats |
| Meissner Filtration Products | ~1–3% | Single-use bag and filter assemblies | Vertically integrated filtration and film supplier |
| Single Use Support GmbH | ~1–2% | Freeze-thaw bag systems, fluid transfer platforms | Cell and gene therapy niche |

## Recent News & Developments

## Recent News & Developments

- European Commission (August 2023): Revised EU GMP Annex 1 became operative, requiring contamination control strategies and favoring closed, pre-sterilized systems, which accelerated container upgrades in sterile manufacturing. [2]
- Lonza Group (March 2024): Agreed to acquire Genentech's Vacaville biologics site for USD 1.2 billion, adding large-scale capacity that will drive ongoing consumable demand. [8]
- Merck KGaA (July 2024): Completed the acquisition of Mirus Bio for about USD 600 million, strengthening viral vector offerings that pair with its single-use assemblies. [17]
- Government of India (August 2024): Cabinet approved the BioE3 policy to build biomanufacturing hubs, supporting new single-use plant construction. [19]
- US House of Representatives (September 2024): Passed the BIOSECURE Act, prompting CDMO customers to review supply chains and qualify alternative vendors. [18]
- Novo Holdings (December 2024): Closed its USD 16.5 billion acquisition of Catalent, consolidating fill-finish and biologics capacity. [3]
- Thermo Fisher Scientific (February 2025): Agreed to acquire Solventum's purification and filtration business for roughly USD 4.1 billion, broadening its single-use fluid-path portfolio. [4]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Covers 2-D, 3-D, and other bioprocess containers used in upstream, downstream, process development, and fill-finish operations by biopharmaceutical manufacturers, CDMOs, and other end users. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 3.97 Billion |
| Market Size in 2035 | USD 14.70 Billion |
| CAGR (2026–2035) | 14.0% |
| Fastest Growing Segments | Contract Development & Manufacturing Organizations (CDMOs) (14.9% CAGR); Downstream Processing (14.6% CAGR); 2-D Bioprocess Containers (14.3% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Thermo Fisher Scientific Inc., Sartorius AG, Danaher Corporation (Cytiva), Merck KGaA, Corning Incorporated, Avantor Inc., Saint-Gobain Life Sciences, Repligen Corporation, Entegris Inc., Meissner Filtration Products, Single Use Support GmbH |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: What extractables and leachables evidence should buyers request from Bioprocess Containers Market suppliers?**
A: Request a supplier extractables study aligned with USP &lt;665&gt; risk categories, including model-solvent data that covers your process conditions [12]. Irradiation dose and contact temperature must match the study's worst case, or the data will not support a regulatory filing.

**Q: How does dual-source qualification reduce container supply risk?**
A: Qualifying two film or assembly sources for each critical bag format lets a site switch suppliers without filing major process changes [13]. Most manufacturers complete comparability testing during clinical phases, when change-control costs remain lowest.

**Q: Can used bioprocess containers be recycled?**
A: Mechanical recycling remains limited because multilayer films combine polyethylene, EVOH, and adhesives that are hard to separate [14]. Current end-of-life routes favor incineration with energy recovery, while pilot programs test pyrolysis to turn used bags into feedstock oil.

**Q: How could the BIOSECURE Act reshape Bioprocess Containers Market sourcing for CDMOs?**
A: The bill, passed by the House in September 2024, targets named biotechnology companies of concern [18]. CDMOs serving US sponsors are reviewing contracts and qualifying alternative container and assembly vendors to avoid disruption if restrictions take effect.

**Q: When does stainless steel remain more economical than single-use containers?**
A: Stainless steel stays competitive for dedicated single-product lines running above 10,000 liters with high annual utilization [7]. In those plants, recurring bag spending can exceed the amortized cleaning and validation costs that disposable formats avoid.

**Q: What container features matter most for cell and gene therapy fill-finish?**
A: These batches need low-volume bags rated for cryogenic storage below minus 150°C, with seal integrity verified after freezing [20]. Closed, pre-sterilized transfer sets also limit open manipulations, which Annex 1 treats as contamination risks [2].

**Q: Which investment signals point to Bioprocess Containers Market consolidation?**
A: Recent deals, including Thermo Fisher's planned purchase of Solventum's filtration unit, show leaders buying adjacent fluid-handling portfolios [4]. Integrated bag, filter, and connector bundles are likely to gain share against single-category suppliers.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/bioprocess-containers-market-6632*